DR. GERE STODDER DIZEREGA, MD
Medical Practice at Mission Rd, Los Angeles, CA
License number
California G30161
Category
Medical Practice
Type
Obstetrics & Gynecology
Address
Address
1321 N Mission Rd, Los Angeles, CA 90033
Phone
(323) 226-4965
Personal information
See more information about GERE STODDER DIZEREGA at radaris.comName
Address
Phone
4491 Greenbrier Pl, Sn Luis Obisp, CA 93401
San Luis Obispo, CA
4491 Greenbrier Pl, Sn Luis Obisp, CA 93401
1270 Hillcrest Ave, Pasadena, CA 91106
1321 Mission Rd, Los Angeles, CA 90033
Professional information
See more information about GERE STODDER DIZEREGA at trustoria.com
Dr. Gere S Dizerega, Los Angeles CA - MD (Doctor of Medicine)
Dr. Gere S Dizerega, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Obstetrics & Gynecology
Address:
LAC USC Medical Center-OB/GYN
1200 N State St, Los Angeles 90033
(323) 226-3416 (Phone)
1200 N State St, Los Angeles 90033
(323) 226-3416 (Phone)
Languages:
English
Dr. Gere S Dizerega, Los Angeles CA - MD (Doctor of Medicine)
Dr. Gere S Dizerega, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Obstetrics & Gynecology
Address:
UNIVERSITY OF SOUTHERN CAL
1321 N Mission Rd SUITE 1013, Los Angeles 90033
(323) 226-4965 (Phone), (323) 225-4035 (Fax)
1321 N Mission Rd SUITE 1013, Los Angeles 90033
(323) 226-4965 (Phone), (323) 225-4035 (Fax)
Languages:
English
Education:
Medical School
Baylor University
Baylor University
Methods For Treating A Patient Undergoing Chemotherapy
Methods For Treating A Patient Undergoing Chemotherapy
US Patent:
6762167, Jul 13, 2004
Filed:
Nov 27, 2000
Appl. No.:
09/723197
Inventors:
Kathleen E. Rodgers - Long Beach CA
Gere S. DiZerega - Los Angeles CA
Gere S. DiZerega - Los Angeles CA
Assignee:
University of Southern California - Los Angeles CA
International Classification:
A61K 3808
US Classification:
514 16, 514 17, 424 91, 530316, 530328, 530329, 435325, 435375
Abstract:
The present invention provides improved methods, kits, and pharmaccutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues. AII fragments or analogues thereof or AII AT type 2 receptor agonists to a patient in need of chemotherapy.
Methods For Treating And Preventing Alopecia
Methods For Treating And Preventing Alopecia
US Patent:
6747008, Jun 8, 2004
Filed:
Nov 27, 2000
Appl. No.:
09/723255
Inventors:
Kathleen E. Rodgers - Long Beach CA
Gere S. DiZerega - Los Angeles CA
Gere S. DiZerega - Los Angeles CA
Assignee:
University of Southern California - Los Angeles CA
International Classification:
A61K 3800
US Classification:
514 17, 514 2, 514 12, 530324, 4241851
Abstract:
The present invention provides improved methods, kits, and pharmaceutical compositions for treating and preventing alopecia in a subject in need thereof by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT type 2 receptor agonists to the subject.
Gere Stodder Dizerega, Los Angeles CA
Gere Stodder Dizerega, Los Angeles CA
Specialties:
OB-GYN
Address:
1321 N Mission Rd, Los Angeles, CA 90033
Methods For Inhibiting Smooth Muscle Cell Proliferation
Methods For Inhibiting Smooth Muscle Cell Proliferation
US Patent:
2002004, Apr 25, 2002
Filed:
Jan 26, 2001
Appl. No.:
09/771192
Inventors:
Kathleen Rodgers - Long Beach CA, US
Gere DiZerega - Los Angeles CA, US
Gere DiZerega - Los Angeles CA, US
International Classification:
A61K038/08
US Classification:
514/016000
Abstract:
The present invention provides improved methods and pharmaceutical compositions for inhibiting smooth muscle cell proliferation, and for treating and preventing conditions associated with smooth muscle cell proliferation, by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII) analogues, AII fragments or analogues thereof or AII ATtype receptor agonists to the subject.
Methods For Treating A Patient Undergoing Chemotherapy
Methods For Treating A Patient Undergoing Chemotherapy
US Patent:
7338938, Mar 4, 2008
Filed:
May 10, 2004
Appl. No.:
10/842877
Inventors:
Kathleen Rodgers - Long Beach CA, US
Gere diZerega - Los Angeles CA, US
Gere diZerega - Los Angeles CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
A61K 38/08, C07K 7/06
US Classification:
514 16, 514 17, 424 91, 530328, 530329, 530316, 435375
Abstract:
The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII) AII analogues, AII fragments or analogues thereof or AII ATtype 2 receptor agonists to a patient in need of chemotherapy.
Use Of Angiotensin Ii Fragments And Analogs Thereof In Tissue Repair
Use Of Angiotensin Ii Fragments And Analogs Thereof In Tissue Repair
US Patent:
2005003, Feb 10, 2005
Filed:
Sep 18, 2003
Appl. No.:
10/667066
Inventors:
Kathleen Rodgers - Long Beach CA, US
Gere Dizerega - Los Angeles CA, US
Gere Dizerega - Los Angeles CA, US
International Classification:
A61K038/17, A61K038/10
US Classification:
514012000, 514013000
Abstract:
Peptides consisting essentially of Angiotensin II fragments and analogs thereof are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical of micellar solutions. The peptides may include amino-terminal and/or carboxy-terminal domains, and/or may be PEGylated to resist peptidase attack yet retain their usefulness for accelerating wound healing.